News

Juncker's team gets the thumbs up
Enlarge image

PoliticsEU

Juncker's team gets the thumbs up

23.10.2014 - Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

Juncker’s proposed Commissioners began presenting themselves and their proposals to MEPs on 29 September. Members of Parliament subjected the Commissioners to cross-examination during the hearings, which ran until 7 October.

After some objections from MEPS, Juncker was obliged to reorganise some appointments in his committee.

Back in September, after announcing his team of Commissioners, the president elect faced criticism when members of Parliament and NGOs attacked his decision to move the control of medicines and pharmaceutical products to the Industry Commissioner.

As a result of ongoing pressure from MEPs and NGOs, Juncker has since retracted his proposal and now the responsibility will stay in the hands of the Health Commissioner.

In response to Juncker’s revised health proposal, Emmanuel Foulon, spokesperson for the Socialists and Democrats (S&D) MEP, said, “Lawmaking, when it comes to pharma issues in Europe, must be put in the right hands. After all, consumers’ health is a right, not a commodity.” 

The 28-strong team, with a Commissioner from each EU Member State, has promised to devise a €300bn programme to help kick-start the languishing EU economy.  


© european-biotechnology-news.com/jc

http://www.european-biotechnology-news.com/news/news/2014-04/junckers-team-gets-the-thumbs-up.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/3.html?cHash=974fa55afb29f60238a626dcfae628dd&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR15.48%
  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%

FLOP

  • MOLOGEN6.60 EUR-13.16%
  • WILEX2.15 EUR-1.83%
  • ADDEX3.40 CHF-1.16%

TOP

  • BIOFRONTERA2.92 EUR32.7%
  • BB BIOTECH157.00 EUR7.2%
  • ADDEX3.40 CHF6.6%

FLOP

  • PAION2.22 EUR-31.9%
  • CYTOS0.17 CHF-19.0%
  • MAGFORCE5.95 EUR-15.6%

TOP

  • SANTHERA84.30 CHF2248.2%
  • CO.DON2.84 EUR202.1%
  • PAION2.22 EUR161.2%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 22.10.2014